دورية أكاديمية
أعرض في EDS

Rejection of benign melanocytic nevi by nevus-resident CD4 + T cells.

التفاصيل البيبلوغرافية
العنوان: Rejection of benign melanocytic nevi by nevus-resident CD4 + T cells.
المؤلفون: Schiferle EB; Center for Cancer Immunology and Cutaneous Biology Research Center, Department of Dermatology, Center for Cancer Research, Massachusetts General Hospital Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA., Cheon SY; Center for Cancer Immunology and Cutaneous Biology Research Center, Department of Dermatology, Center for Cancer Research, Massachusetts General Hospital Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA., Ham S; Department of Biological Sciences, Korea Advanced Institute of Science and Technology, Yuseong Gu, Daejeon, South Korea., Son HG; Center for Cancer Immunology and Cutaneous Biology Research Center, Department of Dermatology, Center for Cancer Research, Massachusetts General Hospital Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA., Messerschmidt JL; Center for Cancer Immunology and Cutaneous Biology Research Center, Department of Dermatology, Center for Cancer Research, Massachusetts General Hospital Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA., Lawrence DP; Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA., Cohen JV; Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA., Flaherty KT; Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA., Moon JJ; Center for Immunology and Inflammatory Diseases and Division of Pulmonary and Critical Care Medicine, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA., Lian CG; Program in Dermatopathology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA., Sullivan RJ; Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA., Demehri S; Center for Cancer Immunology and Cutaneous Biology Research Center, Department of Dermatology, Center for Cancer Research, Massachusetts General Hospital Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA. sdemehri1@mgh.harvard.edu.
المصدر: Science advances [Sci Adv] 2021 Jun 23; Vol. 7 (26). Date of Electronic Publication: 2021 Jun 23 (Print Publication: 2021).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: American Association for the Advancement of Science Country of Publication: United States NLM ID: 101653440 Publication Model: Electronic-Print Cited Medium: Internet ISSN: 2375-2548 (Electronic) Linking ISSN: 23752548 NLM ISO Abbreviation: Sci Adv Subsets: PubMed not MEDLINE; MEDLINE
أسماء مطبوعة: Original Publication: Washington, DC : American Association for the Advancement of Science, [2015]-
مستخلص: Melanoma and melanocytic nevi harbor shared lineage-specific antigens and oncogenic mutations. Yet, the relationship between the immune system and melanocytic nevi is unclear. Using a patient-derived xenograft (PDX) model, we found that 81.8% of the transplanted nevi underwent spontaneous regression, while peripheral skin remained intact. Nevus-resident CD4 + T helper 1 cells, which exhibited a massive clonal expansion to melanocyte-specific antigens, were responsible for nevus rejection. Boosting regulatory T cell suppressive function with low-dose exogenous human interleukin-2 injection or treatment with a human leukocyte antigen (HLA) class II-blocking antibody prevented nevus rejection. Notably, mice with rejected nevus PDXs were protected from melanoma tumor growth. We detected a parallel CD4 + T cell-dominant immunity in clinically regressing melanocytic nevi. These findings reveal a mechanistic explanation for spontaneous nevus regression in humans and posit the activation of nevus-resident CD4 + effector T cells as a novel strategy for melanoma immunoprevention and treatment.
(Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC).)
References: Sci Transl Med. 2015 Mar 18;7(279):279ra39. (PMID: 25787765)
Transplantation. 1983 Jul;36(1):80-4. (PMID: 6223424)
Nature. 2007 Feb 22;445(7130):843-50. (PMID: 17314970)
J Immunol. 2019 Jul 1;203(1):11-19. (PMID: 31209143)
Exp Dermatol. 2019 Jan;28(1):35-44. (PMID: 30326165)
Bioinformatics. 2013 Jan 1;29(1):15-21. (PMID: 23104886)
Nat Rev Immunol. 2002 Jan;2(1):11-9. (PMID: 11908514)
Cell. 2020 Jun 25;181(7):1612-1625.e13. (PMID: 32497499)
Oncogene. 2008 May 1;27(20):2801-9. (PMID: 18193093)
Cancer Gene Ther. 2021 Feb;28(1-2):5-17. (PMID: 32457487)
Nature. 2006 Sep 21;443(7109):340-4. (PMID: 16988713)
Infect Immun. 2003 Aug;71(8):4487-97. (PMID: 12874328)
Proc Natl Acad Sci U S A. 2000 Jan 4;97(1):400-5. (PMID: 10618430)
Arch Dermatol. 2003 Mar;139(3):282-8. (PMID: 12622618)
Nature. 2005 Aug 4;436(7051):720-4. (PMID: 16079850)
Gerontology. 2014;60(2):130-7. (PMID: 24296590)
Cell Mol Gastroenterol Hepatol. 2019;8(2):193-195. (PMID: 31078723)
Nat Biotechnol. 2019 Nov;37(11):1283-1286. (PMID: 31611696)
Int J Cancer. 2019 Mar 1;144(5):1049-1060. (PMID: 30178487)
Nature. 2017 Jul 13;547(7662):217-221. (PMID: 28678778)
Genome Biol. 2014;15(12):550. (PMID: 25516281)
Bioinformatics. 2016 Jan 15;32(2):292-4. (PMID: 26428292)
Cancer Immunol Immunother. 1997 Jun;44(4):239-47. (PMID: 9222283)
Immunol Rev. 1995 Aug;146:57-79. (PMID: 7493761)
Clin Exp Dermatol. 2016 Jul;41(5):552-6. (PMID: 26805629)
J Am Acad Dermatol. 1997 Oct;37(4):620-4. (PMID: 9344203)
J Cutan Pathol. 1989 Apr;16(2):49-53. (PMID: 2668355)
Mol Med Rep. 2020 Oct;22(4):3111-3116. (PMID: 32945463)
Cancer Cell. 2018 Jul 9;34(1):45-55.e4. (PMID: 29990500)
Nat Rev Immunol. 2019 Jan;19(1):7-18. (PMID: 30420705)
Nat Immunol. 2010 Jan;11(1):21-7. (PMID: 20016506)
Int J Oncol. 2009 Feb;34(2):563-72. (PMID: 19148493)
Acta Derm Venereol. 2017 Jun 9;97(6):692-697. (PMID: 28224168)
JCI Insight. 2019 Mar 14;5:. (PMID: 30869654)
PLoS One. 2018 Feb 26;13(2):e0191264. (PMID: 29481571)
N Engl J Med. 2015 Nov 12;373(20):1926-36. (PMID: 26559571)
BMC Bioinformatics. 2011 Aug 04;12:323. (PMID: 21816040)
Nature. 2019 May;569(7755):270-274. (PMID: 31043744)
Nat Rev Immunol. 2015 May;15(5):283-94. (PMID: 25882245)
J Invest Dermatol. 2018 Jul;138(7):1636-1644. (PMID: 29476775)
Int J Toxicol. 2006 Nov-Dec;25(6):499-521. (PMID: 17132609)
J Invest Dermatol. 2016 Oct;136(10):2030-2040. (PMID: 27377700)
Cancer Cell. 2009 Apr 7;15(4):294-303. (PMID: 19345328)
Nat Genet. 2017 May;49(5):659-665. (PMID: 28369038)
Nat Rev Immunol. 2020 Nov;20(11):651-668. (PMID: 32433532)
Nature. 2019 Oct;574(7780):696-701. (PMID: 31645760)
J Exp Med. 1994 Mar 1;179(3):1005-9. (PMID: 8113668)
Br J Dermatol. 2015 Sep;173(3):671-80. (PMID: 25857817)
F1000Res. 2018 Aug 24;7:1338. (PMID: 30254741)
Cancer Immunol Immunother. 2019 Feb;68(2):247-256. (PMID: 30406375)
Immunol Rev. 2008 Apr;222:129-44. (PMID: 18363998)
Br J Dermatol. 1985 Aug;113(2):167-74. (PMID: 4027184)
Nucleic Acids Res. 2015 Dec 2;43(21):e140. (PMID: 26184878)
Anticancer Res. 2011 Nov;31(11):3697-703. (PMID: 22110189)
Immunity. 2013 Feb 21;38(2):373-83. (PMID: 23395677)
Oncogene. 2017 Oct 19;36(42):5771-5792. (PMID: 28604751)
Acta Pharmacol Sin. 2018 Oct;39(10):1553-1558. (PMID: 29620049)
Nature. 2013 Feb 21;494(7437):361-5. (PMID: 23376950)
Immunity. 2015 Nov 17;43(5):896-908. (PMID: 26572061)
Nature. 2017 May 11;545(7653):175-180. (PMID: 28467829)
Nat Rev Immunol. 2018 Oct;18(10):635-647. (PMID: 30057419)
معلومات مُعتمدة: DP5 OD021353 United States OD NIH HHS; R01 AI107020 United States AI NIAID NIH HHS; R01 AR076013 United States AR NIAMS NIH HHS
تواريخ الأحداث: Date Created: 20210624 Latest Revision: 20210814
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC8221625
DOI: 10.1126/sciadv.abg4498
PMID: 34162549
قاعدة البيانات: MEDLINE
الوصف
تدمد:2375-2548
DOI:10.1126/sciadv.abg4498